TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Client Satisfaction Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in Bloating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Preliminary anti-tumoural activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage improvement of lung function FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sense of discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant survival / success rate after one year
Endpoint domain: Mortality/survival
Primary endpoint: Changes on the Mini-Assisting Hand Assessment (Mini-AHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acoustic voice quality index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse disease outcome
Endpoint domain: Adverse events/effects
Primary endpoint: All-cause mortality after 5-years
Endpoint domain: Mortality/survival
Primary endpoint: Composite of all-cause mortality, myocardial infarction, and stroke after 5-years
Endpoint domain: Mortality/survival
Primary endpoint: Composite of all-cause mortality and major amputation of the lower extremities after 5-years
Endpoint domain: Mortality/survival
Primary endpoint: Target limb revascularization after 5-years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: IIEF-5 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Characterize pharmacokinetics (PK) profile of RPT193
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of stress events
Endpoint domain: Adverse events/effects
Primary endpoint: Change of long-term blood glucose concentration measured as glycated hemoglobin at end of follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: oral mucosal pressure injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Tegner Activity Level Scale (TAS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Posttraumatic Stress Disorder Checklist (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Depersonalization Mechanism Scale (DMS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pain at night or at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: core muscles percent fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total calcium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total citratemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Access to number
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Miller-Payne grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of dimpling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate of the tumor (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Positive and Negative Syndrome Scale (PANSS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of all complications
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of all complications (Clavien-Dindo grade ≥ III)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of anastomotic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Need of morphine analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: Patients pain scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of related adverse events per patient
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visuel Analogue Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success rate of complete stone removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ERCP-related complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Vaccine Hesitant Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in symptoms (Jackson score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day incidence of infection
Endpoint domain: Adverse events/effects
Primary endpoint: RMSD of Investigational Device's Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RMSD of Investigational Device's Respiratory Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: RMSD of Predicate Device's Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RMSD of Predicate Device's Respiratory Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Isometric hip flexion strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Volume Change of Nasolabial Folds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Maximum Depth of Nasolabial Folds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mid-Facial Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balanced Dietary Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complications and adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Geometric Mean Titer (GMT) of Serum Immunoglobulin G (IgG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in GMT of Neutralizing (Neut) Antibodies in Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change GMT of serum IgG in Infants Born to Individuals Vaccinated During Pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cortisol Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Distress Thermometer
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of participants with ≥1 adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants discontinuing from study therapy due to AE
Endpoint domain: Adverse events/effects
Primary endpoint: Complications during transcatheter secundum atrial septal defect closure
Endpoint domain: Adverse events/effects
Primary endpoint: Trainee Reaction to the Training
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean deviation of blood pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Standard deviation of blood pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Limited Dose Toxicity (LTD)
Endpoint domain: Adverse events/effects
Primary endpoint: Manual Ability Classification System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Trunk Control Measurement Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABILHAND-Kids: a measure of manual ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shriners Hospital Upper Extremity Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualitative assessment of patient experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Chronic glucose metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful application of Cardio-Oncology assessments and surveillance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom from MACE within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with Grade III-IV acute graft versus host disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: GVHD-free relapse-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of psychological disorders (anxiety, depression, stress)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Financial and economic suffering of infertile couples
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change from Baseline in Hemoglobin value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline in white blood cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Anatomic change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing duration of wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of the trocar placements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of intraoperative respiratory depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: time in target SpO2 range 90%-95%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: skin-pleura distance in sitting position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: skin-pleura distance in prone position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: free fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response to vaccination (antibody titre at 1 month)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune response to vaccination (antibody titre at 3 months)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline percentage of CD8+ TIL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Characterization of the expression and receptor density of prostate lineage antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the collapsibility index (%) of IVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Pulsatility index of IVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of IVC diameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analogue score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biological procoagulant profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients with UACR > 700 mg/g or UPCR > 1000 mg/g
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of patients with eGFR 20-90 mL/min/1.73 m2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fat free mass retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in peripheral arterial disease symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ED visit use or re-hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Eradication of Basal Cell Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dose-limiting toxicity and treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Toxicity (safety)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in intestinal permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Difference from baseline in circulating cortisol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: N/OFQ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Skin Quality Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Global Aesthetic Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in FACE-Q Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Craniovertebral Angle Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients with Post ERCP Pancreatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle demands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cognitive demands
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Origin of fibroblasts from blood-derived monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Presence of cells transitioning from monocytes to fibroblasts in the papillary dermis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC0-inf
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline maximal oxygen uptake (VO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to most effective antimicrobial treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Development of lupus nephritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety of the home-based IMT program
Endpoint domain: Adverse events/effects
Primary endpoint: Post-colonoscopy adenomas at year 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants positive for a non-seasonal influenza virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sleep Scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Amount of rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Teaching Progress Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Observed Classroom Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Child Social-Emotional Functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spontaneous and traumatic bleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: treated spontaneous bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: treated joint bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline in bench press strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in squat strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deterioration of EPIC-26 sexual function domain scores
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: 1-year HBV reactivation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Numerical rating scale (NRS) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain during sustained heat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of esophageal foreign body/food impaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: clinical failure at day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length of stay after diagnosis
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Oswestry Disability Index (ODI)/Neck Disability Index (NDI) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline MDASI-Taiwan Form
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change from Baseline VSH sleep scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from Baseline BFI-Taiwan Form
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change from Baseline EQ-5D
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants compliant with the study procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: length of stay at the ICU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Clinical success for EUS-CD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical success for EUS-GEA and enteral stenting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Acceptance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contact with the Present Moment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of coronary microvascular dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity and specificity of the Panbio™ COVID-19/Flu A&B Rapid Panel device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in blood pressure mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of time that BIS value is maintained between 40 and 60
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in The International Restless Leg Syndrome Study Group (IRLSSG) rating scale for restless legs syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total antibiotic days of therapy (DOT) per 1000 patient-days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Non-inferiority of LEVETIRACETAM compared to PHENYTOIN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hour urine protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevalence of HIV infection
Endpoint domain: Mortality/survival
Primary endpoint: Impact on Social-Emotional Health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum Concentration (Cmax) of Lasmiditan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Lasmiditan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Lasmiditan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vestibulo-ocular reflex (VOR) gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye movement variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyography (EMG) amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyography (EMG) time onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance equilibrium and composite scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe necrotising enterocolitis (NEC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tumor volume assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Grade 1 or higher solicited AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentages of vaccinees with a ≥4-fold rise in HPIV3 neutralizing serum antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentages of vaccinees with a ≥4-fold rise in HMPV-neutralizing serum antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes